Sean McClain, CEO of Absci, and Andreas Busch, Chief Innovation Officer, discuss how AI is revolutionizing drug discovery. They delve into tackling 'undruggable' targets, emphasizing how AI reduces development timelines and costs. Sean shares Absci's shift to biologics and the importance of partnerships with Big Pharma like AstraZeneca. Andreas reflects on his transition from Big Pharma to biotech, highlighting innovation in smaller companies. Together, they explore the future of drug development in an increasingly AI-driven landscape.
